Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

New Pharmaceutical Salts of Trazodone

Version 1 : Received: 23 December 2020 / Approved: 23 December 2020 / Online: 23 December 2020 (13:42:36 CET)

How to cite: Jaśkowska, J.; Zaręba, P.; Drabczyk, A.; Kozak, A.; Madura, I.; Majka, Z.; Pindelska, E. New Pharmaceutical Salts of Trazodone. Preprints 2020, 2020120588 (doi: 10.20944/preprints202012.0588.v1). Jaśkowska, J.; Zaręba, P.; Drabczyk, A.; Kozak, A.; Madura, I.; Majka, Z.; Pindelska, E. New Pharmaceutical Salts of Trazodone. Preprints 2020, 2020120588 (doi: 10.20944/preprints202012.0588.v1).

Abstract

New pharmaceutically acceptable salts of trazodone for the treatment of central nervous system disorders are synthesized and described. Each salt (trazodone hydrogen bromide and trazodone 1-hydroxy-2-naphthoate) was obtained by two or three different methods leading to the same crystalline form. Although trazodone salts are poorly crystalline, single-crystal X-ray diffraction data for trazodone 1-hydroxy-2-naphthoate were collected and analyzed as well as compared to the previously described crystal structure of commercially available trazodone hydrochloride. The powder samples of all new salts were characterized by Fourier transform infrared spectroscopy and 13C solid-state nuclear magnetic resonance spectroscopy. Spectroscopic studies were supported by gauge including projector augmented wave (GIPAW) calculations of carbon chemical shielding constants. The main goal of our research was to find salts with better physicochemical properties and to make an attempt to associate them with both the anion structure and the most prominent interactions exhibited by the protonated trazodone cation. The dissolution profiles of trazodone from tablets prepared from various salts with lactose monohydrate were investigated. The studies revealed that salts with simple anions show a fast release of the drug while the presence of more complex anion, more strongly interacting with the cation, effects a slow-release profile of the active substance and can be used for the preparation of the tables with a delay or prolonged mode of action.

Subject Areas

Trazodone; drug design; dissolution; crystal structure; solid-state NMR (SSNMR) spectroscopy; GIPAW calculation

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.